COVID-19, Kawasaki and the Cytokine Storm
by Sabina Paglialunga, PhD - Director, Scientific Affairs, Celerion SARS-CoV-2 symptoms include feve...
Blog
Capturing the Cytokine Storm: Using Biomarkers in COVID-19 T...
By Sumit Kar, Lead Scientist – Biomarkers, Celerion Cytokine biomarkers are released in the body aft...
Blog
Pharmabiotics – Spreading Culture to Therapeutic Drugs
In the therapeutic toolbox, there is a multitude of drug categories. For decades, small molecules ha...
Blog
COVID-19 Vaccines in Development
COVID-19 Vaccines in Development COVID-19 is a respiratory illness caused by a novel coronavirus. Ac...
Blog
Backing the Biosimilar Boon
Biological therapies such as peptides, enzymes and antibodies have changed the face of medicine, pro...
Blog
Innovations in COPD – A Breath of Fresh Air
Chronic obstructive pulmonary disease (COPD) describes a cluster of diseases linked to breathing pro...
Blog
Entering the NASH Race: Tips for Early Clinical Development
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease that affects over 17 million American...
Blog
The Next Frontier of Pharmacology: Micro Drug Delivery
Injectable medication can be burdensome for the patient, causing pain and discomfort, and can contri...
Blog
Know Your Numbers Campaign
Know Your Numbers Campaign At Celerion, our community outreach does not only serve to inform the pub...